Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era, Blood, vol.117, pp.26-38, 2011. ,
Mantle cell lymphoma: a clinicopathologic study of 80 cases, Blood, vol.89, pp.2067-2078, 1997. ,
Molecular pathogenesis of mantle cell lymphoma, Journal of Clinical Investigation, vol.122, issue.10, pp.3416-3423, 2012. ,
DOI : 10.1172/JCI61272
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma, Blood, vol.126, issue.5, pp.604-611, 2015. ,
DOI : 10.1182/blood-2015-02-628792
URL : https://hal.archives-ouvertes.fr/hal-01543670
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma, Proceedings of the National Academy of Sciences, vol.110, issue.4, pp.18250-18255, 2013. ,
DOI : 10.1073/pnas.1205299110
The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma, Blood, vol.121, issue.16, pp.3161-3164, 2013. ,
DOI : 10.1182/blood-2013-01-478834
Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma, Blood, vol.119, issue.18, pp.4215-4223, 2012. ,
DOI : 10.1182/blood-2011-12-400580
Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma, Cancer Res, vol.70, pp.1408-1418, 2010. ,
Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage, Cancer Cell, vol.30, issue.5, pp.806-821, 2016. ,
DOI : 10.1016/j.ccell.2016.09.014
Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma, Blood, vol.128, issue.24, pp.2808-2818, 2016. ,
DOI : 10.1182/blood-2016-06-720490
Pathogenic role of B-cell receptor signaling and canonical NF-??B activation in mantle cell lymphoma, Blood, vol.128, issue.1, pp.82-92, 2016. ,
DOI : 10.1182/blood-2015-11-681460
The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies, Seminars in Cancer Biology, vol.24, pp.71-81, 2014. ,
DOI : 10.1016/j.semcancer.2013.08.011
The microenvironment in mantle cell lymphoma: Cellular and molecular pathways and emerging targeted therapies, Seminars in Cancer Biology, vol.21, issue.5, pp.308-312, 2011. ,
DOI : 10.1016/j.semcancer.2011.09.006
CCL19 and CXCL12 Trigger in Vitro Chemotaxis of Human Mantle Cell Lymphoma B Cells, Clinical Cancer Research, vol.10, issue.3, pp.964-971, 2004. ,
DOI : 10.1158/1078-0432.CCR-1182-3
Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival, International Journal of Cancer, vol.79, issue.8, pp.2092-2097, 2006. ,
DOI : 10.1046/j.1365-3083.2003.01217.x
Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients, Blood, vol.122, issue.14, pp.2412-2424, 2013. ,
DOI : 10.1182/blood-2013-02-482125
T cell counts in peripheral blood in mantle cell lymphoma, Cancer Science, vol.25, issue.10, pp.1471-1476, 2016. ,
DOI : 10.1007/s10555-006-9001-7
T-Cell Levels Are Prognostic in Mantle Cell Lymphoma, Clinical Cancer Research, vol.20, issue.23, pp.6096-6104, 2014. ,
DOI : 10.1158/1078-0432.CCR-14-0889
URL : http://clincancerres.aacrjournals.org/content/clincanres/20/23/6096.full.pdf
Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma, Blood, vol.107, issue.9, pp.3639-3646, 2006. ,
DOI : 10.1182/blood-2005-08-3376
Mantle cell lymphoma is associated with a variable number of PD-1-positive tumor infiltrating T-cells, Blood, vol.128, pp.5317-5317, 2016. ,
High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells, Blood, vol.121, issue.8, pp.1367-1376, 2013. ,
DOI : 10.1182/blood-2012-04-421826
URL : http://www.bloodjournal.org/content/bloodjournal/121/8/1367.full.pdf
Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells, Haematologica, vol.98, issue.9, pp.1458-1466, 2013. ,
DOI : 10.3324/haematol.2012.071340
Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4, Leukemia, vol.14, issue.2, pp.292-298, 2000. ,
DOI : 10.1038/sj.leu.2401664
Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures, Blood, vol.96, pp.2219-2225, 2000. ,
Mantle cell lymphoma proliferates upon IL-10 in the CD40 system, Leukemia, vol.14, issue.8, pp.1483-1489, 2000. ,
DOI : 10.1038/sj.leu.2401829
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma, Oncotarget, vol.6, issue.11, pp.8750-8759, 2015. ,
DOI : 10.18632/oncotarget.3275
Characteristics of human primary mantle cell lymphoma engraftment in NSG mice, British Journal of Haematology, vol.116, issue.1, pp.165-169, 2016. ,
DOI : 10.1182/blood-2010-01-265769
Absolute monocyte count predicts overall survival in mantle cell lymphomas: correlation with tumour-associated macrophages, Hematological Oncology, vol.23, issue.9, pp.178-186, 2014. ,
DOI : 10.1200/JCO.2005.08.133
Lenalidomide Inhibits Lymphangiogenesis in Preclinical Models of Mantle Cell Lymphoma, Cancer Research, vol.73, issue.24, pp.7254-7264, 2013. ,
DOI : 10.1158/0008-5472.CAN-13-0750
during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease, Leukemia & Lymphoma, vol.96, issue.1, pp.186-193, 2015. ,
DOI : 10.1016/j.semcancer.2012.02.002
Follicular dendritic cells in follicular lymphoma and types of non-Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcome, Histopathology, vol.114, issue.4, pp.586-592, 2011. ,
DOI : 10.1182/blood-2009-06-225326
URL : https://hal.archives-ouvertes.fr/hal-00623321
Growth pattern and distribution of follicular dendritic cells in mantle cell lymphoma: a clinicopathological study of 96 patients, Virchows Archiv, vol.5, issue.2, pp.151-159, 2006. ,
DOI : 10.1093/ajcp/110.5.582
ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy, Clinical Cancer Research, vol.22, issue.1, pp.187-199, 2016. ,
DOI : 10.1158/1078-0432.CCR-15-0987
Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor ??B pathways, Haematologica, vol.97, issue.8, pp.1255-1263, 2012. ,
DOI : 10.3324/haematol.2011.040659
Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting, Blood, vol.113, issue.19, pp.4604-4613, 2009. ,
DOI : 10.1182/blood-2008-10-185827
Anti-JAM-C therapy eliminates tumor engraftment in a xenograft model of mantle cell lymphoma, Journal of Leukocyte Biology, vol.100, issue.5, pp.843-853, 2016. ,
DOI : 10.1189/jlb.1HI1114-549RR
Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma, Cancer Discovery, vol.4, issue.9, pp.1022-1035, 2014. ,
DOI : 10.1158/2159-8290.CD-14-0098
Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases, Blood, vol.118, issue.11, pp.3088-3095, 2011. ,
DOI : 10.1182/blood-2011-03-343434
Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features, Cancer Research, vol.72, issue.20, pp.5307-5316, 2012. ,
DOI : 10.1158/0008-5472.CAN-12-1615
Targeting pathological B cell receptor signalling in lymphoid malignancies, Nature Reviews Drug Discovery, vol.12, issue.3, pp.229-243, 2013. ,
DOI : 10.1016/j.ccr.2007.08.011
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling, Blood, vol.129, issue.6, pp.759-770, 2017. ,
DOI : 10.1182/blood-2016-05-718494
URL : https://hal.archives-ouvertes.fr/hal-01475956
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies, Clin Adv Hematol Oncol, vol.14, pp.55-65, 2016. ,
Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies, Cancer, vol.101, issue.10, pp.2148-2157, 2006. ,
DOI : 10.4049/jimmunol.172.4.2011
Elevated soluble IL-2R??, IL-8, and MIP-1?? levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma, American Journal of Hematology, vol.117, issue.12, pp.223-227, 2014. ,
DOI : 10.1182/blood-2010-05-283820
Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells, Blood, vol.120, issue.18, pp.3783-3792, 2012. ,
DOI : 10.1182/blood-2012-04-424630
CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer, Immunity, vol.44, issue.4, pp.913-923, 2016. ,
DOI : 10.1016/j.immuni.2016.04.003
Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma, International Journal of Cancer, vol.105, issue.12 ,
DOI : 10.1182/blood-2004-10-4054
Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling, Leukemia, vol.91, issue.1, pp.139-148, 2012. ,
DOI : 10.1016/j.cell.2010.07.044
URL : https://hal.archives-ouvertes.fr/inserm-00869028
Distinction between small lymphocytic and mantle cell lymphoma by immunoreactivity for CD23, Mod Pathol, vol.7, pp.326-331, 1994. ,
Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma, Haematologica, vol.95, issue.11, pp.1865-1872, 2010. ,
DOI : 10.3324/haematol.2009.019745
Tampering with cancer chemoresistance by targeting the TGM2-IL6-autophagy regulatory network, Autophagy, vol.13, issue.3, pp.627-628, 2017. ,
DOI : 10.1080/15548627.2016.1271516
Simultaneous Inhibition of CXCR4 and VLA-4 Exhibits Combinatorial Effect in Overcoming Stroma-Mediated Chemotherapy Resistance in Mantle Cell Lymphoma Cells, Immune Network, vol.14, issue.6, pp.296-306, 2014. ,
DOI : 10.4110/in.2014.14.6.296
Pharmacological and genomic profiling identifies NF-??B???targeted treatment strategies for mantle cell lymphoma, Nature Medicine, vol.1, issue.1, pp.87-92, 2014. ,
DOI : 10.1093/bib/bbs017
Constitutive NF-??B and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas, Blood, vol.107, issue.11, pp.4540-4548, 2006. ,
DOI : 10.1182/blood-2005-10-4042
Inhibition of Constitutive NF-??B Activation in Mantle Cell Lymphoma B Cells Leads to Induction of Cell Cycle Arrest and Apoptosis, The Journal of Immunology, vol.171, issue.1, pp.88-95, 2003. ,
DOI : 10.4049/jimmunol.171.1.88
Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray, Blood, vol.98, issue.3, pp.787-794, 2001. ,
DOI : 10.1182/blood.V98.3.787
URL : http://www.bloodjournal.org/content/bloodjournal/98/3/787.full.pdf
Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells, Blood, vol.123, issue.6, pp.884-893, 2014. ,
DOI : 10.1182/blood-2013-04-499079
URL : http://www.bloodjournal.org/content/bloodjournal/123/6/884.full.pdf
Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a, Blood, vol.116, issue.24, pp.5228-5236, 2010. ,
DOI : 10.1182/blood-2010-03-275925
Treatment of Older Patients with Mantle-Cell Lymphoma, New England Journal of Medicine, vol.367, issue.6, pp.520-531, 2012. ,
DOI : 10.1056/NEJMoa1200920
Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group, p.2016, 2017. ,
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network, The Lancet, vol.388, issue.10044, pp.565-575, 2016. ,
DOI : 10.1016/S0140-6736(16)00739-X
Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study, Journal of Clinical Oncology, vol.31, issue.29, pp.3688-3695, 2013. ,
DOI : 10.1200/JCO.2013.49.2835
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial, The Lancet Oncology, vol.13, issue.7, pp.716-723, 2012. ,
DOI : 10.1016/S1470-2045(12)70200-0
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers, Haematologica, vol.97, issue.3, pp.416-422, 2012. ,
DOI : 10.3324/haematol.2011.051813
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma, Journal of Clinical Oncology, vol.33, issue.25, pp.2803-2811, 2015. ,
DOI : 10.1200/JCO.2014.59.5363
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial, The Lancet Oncology, vol.15, issue.1, pp.69-77, 2014. ,
DOI : 10.1016/S1470-2045(13)70551-5
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study, Annals of Oncology, vol.20, issue.3, pp.520-525, 2009. ,
DOI : 10.1093/annonc/mdn656
Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma, Haematologica, vol.96, issue.7, pp.1008-1014, 2011. ,
DOI : 10.3324/haematol.2011.041392
URL : http://www.haematologica.org/content/haematol/96/7/1008.full.pdf
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma, New England Journal of Medicine, vol.369, issue.6, pp.507-516, 2013. ,
DOI : 10.1056/NEJMoa1306220
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513941/pdf
Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma, British Journal of Haematology, vol.369, issue.1, pp.131-134, 2015. ,
DOI : 10.1056/NEJMoa1306220
URL : http://onlinelibrary.wiley.com/doi/10.1111/bjh.13275/pdf
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity, Blood, vol.123, issue.12, pp.1957-1960, 2014. ,
DOI : 10.1182/blood-2014-01-547869
URL : http://www.bloodjournal.org/content/bloodjournal/123/12/1957.full.pdf
Targeting neoplastic B cells and harnessing microenvironment: the ???double face??? of ibrutinib and idelalisib, Journal of Hematology & Oncology, vol.88, issue.6, p.60, 2015. ,
DOI : 10.1002/ajh.23433
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Journal of Clinical Oncology, vol.35, issue.8, pp.826-833, 2017. ,
DOI : 10.1200/JCO.2016.70.4320